Kamada (KMDA) Competitors $7.45 +0.02 (+0.27%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$7.43 -0.02 (-0.27%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KMDA vs. IMCR, SPRY, ADPT, TARS, ETNB, SDGR, JANX, VERA, TVTX, and EWTXShould you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Adaptive Biotechnologies (ADPT), Tarsus Pharmaceuticals (TARS), 89BIO (ETNB), Schrodinger (SDGR), Janux Therapeutics (JANX), Vera Therapeutics (VERA), Travere Therapeutics (TVTX), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry. Kamada vs. Its Competitors Immunocore ARS Pharmaceuticals Adaptive Biotechnologies Tarsus Pharmaceuticals 89BIO Schrodinger Janux Therapeutics Vera Therapeutics Travere Therapeutics Edgewise Therapeutics Kamada (NASDAQ:KMDA) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk. Does the media refer more to KMDA or IMCR? In the previous week, Immunocore's average media sentiment score of 1.54 beat Kamada's score of 0.00 indicating that Immunocore is being referred to more favorably in the news media. Company Overall Sentiment Kamada Neutral Immunocore Very Positive Which has more volatility & risk, KMDA or IMCR? Kamada has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Do institutionals & insiders believe in KMDA or IMCR? 20.4% of Kamada shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 10.4% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend KMDA or IMCR? Kamada presently has a consensus price target of $13.00, indicating a potential upside of 74.50%. Immunocore has a consensus price target of $58.89, indicating a potential upside of 62.18%. Given Kamada's stronger consensus rating and higher probable upside, research analysts plainly believe Kamada is more favorable than Immunocore.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Immunocore 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55 Is KMDA or IMCR more profitable? Kamada has a net margin of 9.60% compared to Immunocore's net margin of -6.48%. Kamada's return on equity of 6.31% beat Immunocore's return on equity.Company Net Margins Return on Equity Return on Assets Kamada9.60% 6.31% 4.43% Immunocore -6.48%-5.86%-2.09% Which has preferable valuation & earnings, KMDA or IMCR? Kamada has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$160.95M2.66$14.46M$0.2925.69Immunocore$310.20M5.88-$51.09M-$0.43-84.44 SummaryKamada beats Immunocore on 10 of the 15 factors compared between the two stocks. Get Kamada News Delivered to You Automatically Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KMDA vs. The Competition Export to ExcelMetricKamadaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$428.41M$2.94B$5.54B$9.42BDividend YieldN/A2.48%3.76%4.04%P/E Ratio25.6919.8828.2619.78Price / Sales2.66306.86415.2388.82Price / Cash15.1541.8435.8558.18Price / Book1.657.678.115.65Net Income$14.46M-$55.28M$3.25B$257.97M7 Day Performance-3.87%4.87%1.63%3.74%1 Month Performance3.47%13.14%7.62%11.95%1 Year Performance28.89%3.51%32.74%19.22% Kamada Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KMDAKamada3.845 of 5 stars$7.45+0.3%$13.00+74.5%+28.9%$428.41M$160.95M25.69360Positive NewsIMCRImmunocore1.4765 of 5 stars$35.30+0.8%$58.89+66.8%-8.7%$1.77B$310.20M-82.09320Positive NewsSPRYARS Pharmaceuticals3.0733 of 5 stars$17.90+1.2%$31.00+73.2%+70.0%$1.76B$97.12M-111.8790ADPTAdaptive Biotechnologies2.9715 of 5 stars$11.55-2.3%$10.57-8.5%+157.2%$1.75B$178.96M-12.03790TARSTarsus Pharmaceuticals1.6458 of 5 stars$41.53+6.0%$66.67+60.5%+59.9%$1.74B$182.95M-15.2150News CoverageAnalyst RevisionGap UpETNB89BIO2.1467 of 5 stars$11.12+1.1%$26.43+137.7%+25.6%$1.62BN/A-3.2940News CoverageInsider TradeSDGRSchrodinger2.0399 of 5 stars$21.14+0.6%$32.75+54.9%+0.4%$1.55B$207.54M-8.04790News CoveragePositive NewsJANXJanux Therapeutics2.2544 of 5 stars$26.18+4.1%$91.89+251.0%-40.9%$1.55B$9.34M-19.2530News CoverageVERAVera Therapeutics4.0713 of 5 stars$23.78-0.2%$65.00+173.3%-33.5%$1.52BN/A-7.9340TVTXTravere Therapeutics3.6957 of 5 stars$16.91+2.7%$32.14+90.1%+64.4%$1.50B$233.18M-6.02460News CoveragePositive NewsAnalyst RevisionEWTXEdgewise Therapeutics1.2288 of 5 stars$13.93+0.7%$40.00+187.2%-36.6%$1.47BN/A-8.9960News Coverage Related Companies and Tools Related Companies Immunocore Alternatives ARS Pharmaceuticals Alternatives Adaptive Biotechnologies Alternatives Tarsus Pharmaceuticals Alternatives 89BIO Alternatives Schrodinger Alternatives Janux Therapeutics Alternatives Vera Therapeutics Alternatives Travere Therapeutics Alternatives Edgewise Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KMDA) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KMDA Stock Alerts